Diagnosis and Assessment
6
Coreceptor Tropism Assay
Î Tropism testing should be performed if the use of a CCR5 antagonist
is being considered (SR-H).
Laboratory Tests
Complete Blood Cell Count and Chemistry Panel
Î A complete blood cell count with differential white blood cell count
and chemistry panel should be obtained upon initiation of care (SR-H).
Glucose-6-Phosphate Dehydrogenase
Î Screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency
is recommended upon entry into care or before starting therapy
with an oxidant drug in patients with a predisposing racial or ethnic
background (SR-M).
Fasting Lipid Profile
Î Because many antiretroviral drugs, HIV infection itself, and host factors
are associated with increased cholesterol and triglyceride levels, a
fasting lipid profile should be obtained upon initiation of care (SR-H).
HLA B*5701 Screening
Î HLA-B*5701 testing should be performed before initiating abacavir
therapy (SR-H).
Î Patients who are positive for the HLA B*5701 haplotype are at high
risk for hypersensitivity reaction and should NOT be treated with
abacavir (SR-H).
Urinalysis and Calculated Creatinine Clearance
Î A baseline urinalysis should be performed and baseline calculated
creatinine clearance or estimated glomerular filtration rate should
be obtained, especially in black HIV-infected patients and those with
advanced disease or comorbid conditions, because of an increased
risk of nephropathy (SR-H).
Î Urinalysis and calculated creatinine clearance assay should also be
performed prior to initiating the use of drugs that have the potential
for nephrotoxicity such as tenofovir or indinavir (SR-M).
